UBS Maintains Buy on MapLight Therapeutics, Raises Price Target to $52

Benzinga Newsdesk www.benzinga.com Positive 83.4%

Neg 0% Neu 0% Pos 83.4%

UBS analyst Ashwani Verma maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $48 to $52.